Anshula Gautam

Anshula Gautam

Active Director Director DIN 06955149
DIN 06955149 First appointment Sep 2014 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 5 active board seats
Past companies 2 historical roles
Total affiliations 7 Since Sep 2014
Shareholding value •••• Premium profile

About Anshula Gautam

Data last updated:

Anshula Gautam is a Director at Clinical Research Network India Private Limited (since 2015), Director at Cms Clinical Research Private Limited (since 2014) and Director at Provaxa Health Sciences Private Limited (since 2026), and holds 2 more current directorships. The companies operate in Healthcare, Travel and Hospitality and Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹29.72 Cr; the largest is Clinical Research Network India Private Limited at ₹29.26 Cr (FY 2024). Earlier, Anshula Gautam was a Director at Microalter Technology Private Limited (from 2022) and Director at Kyra Immunological Research Opc Private Limited (from 2014).

DIN 06955149
Primary Designation Director
Industry Healthcare
First Appointment 01 Sep 2014
Oldest Company Age 12 yrs
Largest company Clinical Research Network India Private Limited · ₹29.26 Cr (FY 2024)
Combined revenue ₹29.72 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director16 Dec 20152015₹29.26 Cr (FY 2024)Active
Director28 Nov 20142014₹45.9 Lakh (FY 2025)Active
Director01 Jan 20262026Active
Marici Innovations Private Limited U86201DL2023PTC423384
Director04 Dec 20232023Active
Health For All Foundation U85300DL2020NPL361550
Director07 Feb 20202020Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director16 Jun 20222022Strike Off
Director01 Sep 20142014Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Microalter Technology Private Limited
Cms Clinical Research Private Limited
Clinical Research Network India Private Limited
Health For All Foundation
Premium access

Shareholding and investment profile for Anshula Gautam

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anshula Gautam

Anshula Gautam currently holds 5 directorships: Clinical Research Network India Private Limited (Director, since 16 Dec 2015, revenue ₹29.26 Cr (FY 2024)); Cms Clinical Research Private Limited (Director, since 28 Nov 2014, revenue ₹45.9 Lakh (FY 2025)); Provaxa Health Sciences Private Limited (Director, since 01 Jan 2026); Marici Innovations Private Limited (Director, since 04 Dec 2023); Health For All Foundation (Director, since 07 Feb 2020).

Anshula Gautam was first appointed on 01 Sep 2014 as Director at Kyra Immunological Research Opc Private Limited. The most recent appointment on record is 01 Jan 2026 at Provaxa Health Sciences Private Limited.

The 2 current companies of Anshula Gautam that report revenue have a combined latest revenue of ₹29.72 Cr: Clinical Research Network India Private Limited ₹29.26 Cr (FY 2024); Cms Clinical Research Private Limited ₹45.9 Lakh (FY 2025).

Anshula Gautam held 2 earlier board appointments: Microalter Technology Private Limited (Director, from 16 Jun 2022); Kyra Immunological Research Opc Private Limited (Director, from 01 Sep 2014).

The current boards of Anshula Gautam's companies include Anit Singh (Clinical Research Network India Private Limited), Nidhi Singh (Clinical Research Network India Private Limited), Priya Shukla (Marici Innovations Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available